X4 PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
X4 PHARMACEUTICALS, INC (XFOR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $4.50 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-11.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2019-03-11
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-03-31 was $200.00K, a 0.00% change year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2017-03-31 was $200.00K.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2018 was $4.50M, a 462.50% increase from fiscal 2017.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2017 was $800.00K, a 60.00% increase from fiscal 2016.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2016 was $500.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|
| 2018-12-31 | $4.50M 10-K · filed 2019-03-11 | |
| 2018-03-31 | $200.00K 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $800.00K 10-K · filed 2019-03-11 | |
| 2017-03-31 | $200.00K 10-Q · filed 2018-05-10 | |
| 2016-12-31 | $500.00K 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |